In symptomatic PAH, adding sotatercept to stable background therapy improved 6-min walk distance at 24 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37276594.
- Also identified by DOI 10.7326/J23-0034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. <b>Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension.</b> N Engl J Med. 2023;388:1478-1490. 36877098.
Medical subject headings
- Hypertension, Pulmonary